Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Uwe Liebchen

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Scientific Reports|August 27, 2021
Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation studyUwe Liebchen, Hanna Salletmeier, Simon Kallee, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2014
Unbound fraction of ertapenem in intensive care unit patientsUwe Liebchen, Alexander Kratzer, Sebastian G Wicha, et al.
Therapeutic Drug Monitoring|November 13, 2020
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples"Uwe Liebchen, Christoph Dorn, Martin Kees, et al.
Scientific Reports|May 14, 2021
Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot studyChristina Scharf, Uwe Liebchen, Michael Paal, et al.
Frontiers in Medicine|November 6, 2023
Pharmacokinetics of immunosuppressive agents during hemoperfusion in a sheep modelBettina Leber, Uwe Liebchen, Lisa Rohrhofer, et al.
Biomedicines|February 26, 2025
Lactate Clearance of the Adsorber Cytosorb<sup>®</sup> in Critically Ill Patients: A Post-Hoc Analysis of the Cyto-SOLVE TrialVassilissa Wustrow, Caroline Gräfe, Helen Graf, et al.
Journal of Intensive Care|December 9, 2020
The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcomeChristina Scharf, Uwe Liebchen, Michael Paal, et al.
Journal of Critical Care|October 10, 2021
Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational studyUwe Liebchen, Michael Paal, Veronika Bucher, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 6, 2021
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serumKatharina Habler, Mathias Brügel, Daniel Teupser, et al.
Antibiotics (Basel, Switzerland)|April 5, 2020
Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness-Experience and Recommendations from One Year in Routine Clinical PracticeChristina Scharf, Michael Paal, Ines Schroeder, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Scientific Reports|August 27, 2021
Optimal loading dose of meropenem before continuous infusion in critically ill patients: a simulation studyUwe Liebchen, Hanna Salletmeier, Simon Kallee, et al.
The Journal of Antimicrobial Chemotherapy|June 26, 2014
Unbound fraction of ertapenem in intensive care unit patientsUwe Liebchen, Alexander Kratzer, Sebastian G Wicha, et al.
Therapeutic Drug Monitoring|November 13, 2020
Comment on "Meropenem, Cefepime, and Piperacillin Protein Binding in Patient Samples"Uwe Liebchen, Christoph Dorn, Martin Kees, et al.
Scientific Reports|May 14, 2021
Successful elimination of bilirubin in critically ill patients with acute liver dysfunction using a cytokine adsorber and albumin dialysis: a pilot studyChristina Scharf, Uwe Liebchen, Michael Paal, et al.
Frontiers in Medicine|November 6, 2023
Pharmacokinetics of immunosuppressive agents during hemoperfusion in a sheep modelBettina Leber, Uwe Liebchen, Lisa Rohrhofer, et al.
Biomedicines|February 26, 2025
Lactate Clearance of the Adsorber Cytosorb<sup>®</sup> in Critically Ill Patients: A Post-Hoc Analysis of the Cyto-SOLVE TrialVassilissa Wustrow, Caroline Gräfe, Helen Graf, et al.
Journal of Intensive Care|December 9, 2020
The higher the better? Defining the optimal beta-lactam target for critically ill patients to reach infection resolution and improve outcomeChristina Scharf, Uwe Liebchen, Michael Paal, et al.
Journal of Critical Care|October 10, 2021
Trough concentrations of meropenem and piperacillin during slow extended dialysis in critically ill patients with intermittent and continuous infusion: A prospective observational studyUwe Liebchen, Michael Paal, Veronika Bucher, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 6, 2021
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serumKatharina Habler, Mathias Brügel, Daniel Teupser, et al.
Antibiotics (Basel, Switzerland)|April 5, 2020
Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness-Experience and Recommendations from One Year in Routine Clinical PracticeChristina Scharf, Michael Paal, Ines Schroeder, et al.
Pageof 7